Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. develops locally delivered, extended-release drug candidates using its proprietary Diffusphere technology, a polymer-based microsphere platform for targeted, controlled delivery. The company's news centers on clinical development of EP-104GI in eosinophilic esophagitis and EP-104IAR in knee osteoarthritis pain, including RESOLVE trial data, tissue-health and symptom measures, endoscopic and histologic scoring, and scientific conference presentations.
Recurring updates also cover financial results, clinical-supply and balance-sheet commentary, investor conference activity, and governance changes as Eupraxia advances its gastrointestinal and pain-focused development programs on Nasdaq and the TSX under EPRX.
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) reported Q1 2026 results and clinical progress for EP-104GI in Eosinophilic Esophagitis.
Net loss was $12.7 million versus $6.8 million a year earlier. Cash and equivalents were $58.5 million plus $80.4 million in short-term investments, supported by a completed $63.2 million public offering.
The company reports robust, durable responses in the highest-dose cohort of the RESOLVE trial and expects existing cash and warrant proceeds to fund operations into H2 2028. As of March 31, 2026, there were 61.8 million common and 8.4 million preferred shares outstanding.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) released first EoEHSS sub score data from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis, presented at Digestive Disease Week on May 6, 2026. Improvements in inflammation (EoEHSS-i) and architecture/fibrosis (EoEHSS-a) were reported at 12 weeks (n=31) and 36 weeks (n=27).
The largest responses occurred in the highest-dose cohort (cohort 9): EoEHSS-i grade and stage improved by >90% at weeks 12 and 36; EoEHSS-a grade and stage improved by >83% at weeks 12 and 36. Some cohort 36-week data remain pending (cohort 8b).
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported EREFS endoscopic data from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis on May 5, 2026. The data show an association between the number of injections and EREFS improvement, with a 20-injection protocol producing the largest mean EREFS reduction.
Among 7 patients with baseline EREFS >2 who received 20 injections, mean EREFS fell by 65% (3.6 points) at week 12; highest-dose cohorts (8b and 9, combined n=4) showed near-complete EREFS improvement.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced on May 1, 2026 the appointment of Dr. Jeymi Tambiah as Chief Medical Officer and the retirement of Dr. Mark Kowalski, who will support the company as a senior consultant during transition.
Dr. Tambiah brings over 18 years of clinical development, regulatory and commercialization experience and will support late‑stage development of EP‑104GI in eosinophilic esophagitis and expansion of the gastroenterology pipeline using the Diffusphere™ platform.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) will present four abstracts at Digestive Disease Week (May 2-5, 2026) in Chicago, including an oral presentation May 3 and three posters May 5 reporting clinical data from the Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE).
The company will host a virtual investor event May 4 at 7am CT featuring KOLs discussing recurrent esophageal strictures and EP-104GI’s potential to prevent strictures; materials will be posted on Eupraxia’s website after presentations.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported 36-week tissue health and symptom results for the highest dose cohort (Cohort 9) in its Phase 1b/2a RESOLVE trial for eosinophilic esophagitis.
Cohort 9 (n=3) showed a 90% EoEHSS Stage reduction, 88% Grade reduction, 72% PEC reduction, and 66% clinical remission maintained from week 8 through week 36. No drug-related SAEs or cases of oropharyngeal candidiasis were reported across 31 patients and >230 patient-months.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced management will present at two investor conferences in April 2026: Raymond James Biotech Innovation Symposium (1x1 meetings) on April 14, 2026 in New York, and Bloom Burton & Co. Healthcare Investor Conference (presentation and 1x1 meetings) on April 21-22, 2026 in Toronto.
The company will present on April 21 at 11:00 AM ET and provide a webcast for investors at the listed link.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported 24-week symptom data from the highest dose cohort in the Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis. Cohort 9 (n=3) showed a mean SDI reduction of 4.0 points at 24 weeks (3 points = clinical remission).
Pooled cohorts 4-9 showed clinical remission in 59% at 12 weeks (13/22), 76% at 24 weeks (13/17), and 67% at 52 weeks (6/9). No SAEs reported across 31 patients and >220 patient-months; no oropharyngeal candidiasis observed.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q4 2025 results, highlighted by clinical progress in its lead program EP-104GI and strengthened liquidity from a Feb 20, 2026 public offering.
Key figures: net loss $16.7M for Q4 2025, cash $80.5M at Dec 31, 2025, and an offering that raised approximately $63.2M. Management expects funding into the second half of 2028.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced the closing of a public offering on Feb 20, 2026 raising approximately US$63.2 million gross from 7,607,145 common shares and pre-funded warrants, including full exercise of the underwriter option. Proceeds will fund EP-104GI clinical development, manufacturing, R&D and corporate purposes.